Skip to main content

Lymphedema, Secondary

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Lower extremity LymphoscintigraphyN/A1 trial
Active Trials
NCT04588493Completed5Est. Dec 2017
Lymphatica Medtech
Lymphatica MedtechSwitzerland - Lausanne
1 program
LymphoPilotN/A1 trial
Active Trials
NCT04858230Terminated12Est. Sep 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lymphatica MedtechLymphoPilot
Angeles TherapeuticsLower extremity Lymphoscintigraphy

Clinical Trials (2)

Total enrollment: 17 patients across 2 trials

LymphoPilot Test for Limb Lymphedema

Start: Sep 2021Est. completion: Sep 202312 patients
N/ATerminated
NCT04588493Angeles TherapeuticsLower extremity Lymphoscintigraphy

Secondary Lymphedema Due to Human Adjuvant Disease

Start: Mar 2017Est. completion: Dec 20175 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.